Patrick M. Lynch

The University of Texas MD Anderson Cancer Center

Full Professor(heuristic)

Genetic factors in colorectal cancer · Pathology and Forensic Medicine

h-index70

i10-index195

Publications541

Citations22,044

Grants

10 total · 0 active

NIH #N01CN005126-000

PHASE II CLINICAL TRIAL OF CELECOXIB IN PERSONS WITH GE

Amount: $3.3M
Period: 2000-09-30 → 2005-09-29
PIs: 1
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #N01CN075021-003

PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE

Amount: $0K
Period: 1997-04-30 → 2001-12-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #N01CN075021-002

PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE

Amount: —
Period: 1997-04-30 → 2000-09-29
PIs: 1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

10 total · 0 active

NIH #N01CN005126-000

PHASE II CLINICAL TRIAL OF CELECOXIB IN PERSONS WITH GE

Amount: $3.3M
Period: 2000-09-30 → 2005-09-29
PIs: 1
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #N01CN075021-003

PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE

Amount: $0K
Period: 1997-04-30 → 2001-12-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #N01CN075021-002

PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE

Amount: —
Period: 1997-04-30 → 2000-09-29
PIs: 1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #N01CN075021-000

PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE

Amount: $1.5M
Period: 1997-04-30 → 1999-07-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #1R03CA051646-01

CALCIUM MODULATION OF COLON CANCER INTERMEDIATE MARKERS

Amount: $35K
Period: 1989-09-10 → 1990-08-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #N01CA095040-8-0-0

A THREE ARM PHASE II CHEMOPREVENTION TRIAL IN ADENOMATOUS POLYPOSIS CO-261095040

Amount: —
Period: — → —
PIs: 1

Awarded at UNIVERSITY OF TEXAS/MD ANDERSO

NIH #N01CN005126-5-0-0

PHASE II CLINICAL TRIAL OF CELECOXIB IN PERSONS WITH GENOTYPE POSITIV-261005126

Amount: —
Period: — → —
PIs: 1

Awarded at UNIVERSITY OF TEXAS/MD ANDERS

NIH #N01CN005126-3-0-0

PHASE II CLINICAL TRIAL OF CELECOXIB IN PERSONS WITH GENOTYPE POSITIV-261005126

Amount: —
Period: — → —
PIs: 1

Awarded at UNIVERSITY OF TEXAS/MD ANDERS

NIH #N01CN005126-1-0-0

PHASE II CLINICAL TRIAL OF CELECOXIB IN PERSONS WITH GENOTYPE POSITIV-261005126

Amount: —
Period: — → —
PIs: 1

Awarded at UNIVERSITY OF TEXAS/MD ANDERS

NIH #N01CN075021-001

PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE

Amount: $472K
Period: 1997-04-30 → —
PIs: 1
Est. capacity / PI: ~7 students

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0203

PageRank within Pathology and Forensic Medicine co-authorship network

Explore collaboration map

Admission Signals

New paper: Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signatures (Nature Communications)2026-04-03

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0003-0125-3109

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 50

Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signatures
Nature Communications · 2026-04-03
A history of the collaborative group of the Americas on inherited gastrointestinal cancer (CGA-IGC): 1995–2025
Familial Cancer · 2026-01-31
Supplementary Figure S1 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Materials and Methods 1 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Figure S8 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Table S2 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Table S5 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Table S8 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Table S6 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Table S7 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Table S4 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Figure S3 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Figure S2 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Table S3 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Figure S4 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Figure S7 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Figure S5 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Figure S6 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Table S1 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
2025-11-25
Supplementary Table 20 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
2025-11-03

Open author page on OpenAlex →